These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32652442)

  • 1. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
    Xiong Y; Guo Y; Liu Y; Wang H; Gong W; Liu Y; Wang X; Gao Y; Yu F; Su D; Wang F; Zhu Y; Zhao Y; Wu Y; Qin Z; Sun X; Ren B; Jiang B; Jin W; Shen Z; Tang Z; Song X; Wang L; Liu X; Zhou C; Jiang B
    Neoplasia; 2020 Sep; 22(9):431-440. PubMed ID: 32652442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
    Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
    J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
    Staniszewska AD; Pilger D; Gill SJ; Jamal K; Bohin N; Guzzetti S; Gordon J; Hamm G; Mundin G; Illuzzi G; Pike A; McWilliams L; Maglennon G; Rose J; Hawthorne G; Cortes Gonzalez M; Halldin C; Johnström P; Schou M; Critchlow SE; Fawell S; Johannes JW; Leo E; Davies BR; Cosulich S; Sarkaria JN; O'Connor MJ; Hamerlik P
    Clin Cancer Res; 2024 Apr; 30(7):1338-1351. PubMed ID: 37967136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
    Stradella A; Johnson M; Goel S; Park H; Lakhani N; Arkenau HT; Galsky MD; Calvo E; Baz V; Moreno V; Saavedra O; Luen SJ; Mu S; Wan Q; Chang V; Zhang W; Barve M
    Cancer Med; 2024 Jul; 13(13):e7385. PubMed ID: 38970256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
    van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
    Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
    Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibition in UV-associated angiosarcoma preclinical models.
    Weidema ME; Desar IME; Hillebrandt-Roeffen MHS; van Erp AEM; Masuzawa M; ; Flucke UE; van der Graaf WTA; Versleijen-Jonkers YMH
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2579-2590. PubMed ID: 34085099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
    Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
    J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
    Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
    Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
    Front Immunol; 2021; 12():762989. PubMed ID: 34975854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamiparib: First Approval.
    Markham A
    Drugs; 2021 Jul; 81(11):1343-1348. PubMed ID: 34287805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.